Discovery and Optimization of Tambjamines as a Novel Class of Antileishmanial Agents
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00517 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Papireddy Kancharla und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Portland State University, Portland, Oregon 97201, United States. Hauptthemen laut MEDLINE: Antiprotozoal Agents, Leishmania donovani, Leishmania mexicana. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Leishmaniasis is a neglected tropical disease that is estimated to afflict over 12 million people. Current drugs for leishmaniasis suffer from serious deficiencies, including toxicity, high cost, modest efficacy, primarily parenteral delivery, and emergence of widespread resistance. We have discovered and developed a natural product-inspired tambjamine chemotype, known to be effective against Plasmodium spp, as a novel class of antileishmanial agents. Herein, we report in vitro and in vivo antileishmanial activities, detailed structure-activity relationships, and metabolic/pharmacokinetic profiles of a large library of tambjamines. A number of tambjamines exhibited excellent potency against both Leishmania mexicana and Leishmania donovani parasites with good safety and metabolic profiles. Notably, tambjamine 110 offered excellent potency and provided partial protection to leishmania-infected mice at 40 and/or 60 mg/kg/10 days of oral treatment. This study presents the first account of antileishmanial activity in the tambjamine family and paves the way for the generation of new oral antileishmanial drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Portland State University, Portland, Oregon 97201, United States.
- Department of Molecular Microbiology and Immunology, Oregon Health & Science University, Portland, Oregon 97239, United States.
- Department of Veterans Affairs Medical Center, Portland, Oregon 97239, United States.
- Experimental Therapeutics Branch, CIDR, Walter Reed Army Institute of Research, Silver Spring, Maryland 20910, United States.
ORCID-Profile: Papireddy Kancharla, Corinne M Fargo, Rozalia A Dodean, Kevin A Reynolds, Jane X Kelly, Scott M Landfear
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Kancharla, P., Ortiz, D., Fargo, C. M., Zhang, X., Li, Y., Sanchez, M., Kumar, A., Yeluguri, M., Dodean, R. A., Caridha, D., Madejczyk, M. S., Martin, M., Jin, X., Blount, C., Chetree, R., Pannone, K., Dinh, H. T., DeLuca, J., Evans, M., …, & Landfear, S. M. (2024). Discovery and Optimization of Tambjamines as a Novel Class of Antileishmanial Agents. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00517
Vancouver
Kancharla P, Ortiz D, Fargo CM, Zhang X, Li Y, Sanchez M, et al. Discovery and Optimization of Tambjamines as a Novel Class of Antileishmanial Agents. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00517
BibTeX
@article{Kancharla2024,
author = {Kancharla, Papireddy and Ortiz, Diana and Fargo, Corinne M and Zhang, Xiaowei and Li, Yuexin and Sanchez, Marco and Kumar, Amrendra and Yeluguri, Monish and Dodean, Rozalia A and Caridha, Diana and Madejczyk, Michael S and Martin, Monica and Jin, Xiannu and Blount, Cameron and Chetree, Ravi and Pannone, Kristina and Dinh, Hieu T and DeLuca, Jesse and Evans, Martin and Nadeau, Robert and Vuong, Chau and Leed, Susan and Dennis, William E and Roncal, Norma and Pybus, Brandon S and Lee, Patricia J and Roth, Alison and Reynolds, Kevin A and Kelly, Jane X and Landfear, Scott M},
title = {Discovery and Optimization of Tambjamines as a Novel Class of Antileishmanial Agents},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00517}
}
EUVIMED